In May, Lupita Nyong’o underwent a second myomectomy to remove more than 50 uterine fibroids. When she discussed the surgery publicly this summer, the update drew attention for understandable reasons. It was personal, difficult, and still recent.

But by the time that disclosure made headlines, the attention around her experience already had somewhere to go.

Earlier in the year, Nyong’o launched “Make Fibroids Count” with the Foundation for Women’s Health. The campaign was created to support a research grant focused on non-invasive and minimally invasive approaches to uterine fibroids. It has raised more than $230,000, surpassing its original $200,000 goal.

That sequence is worth examining.

A celebrity health disclosure can create awareness quickly. A stronger partnership decides what that awareness is supposed to make possible.

Attention is only the opening condition

When a public figure shares a health experience, news coverage can move faster than the campaign around it.

The disclosure becomes the story. Headlines summarize the diagnosis, treatment, symptoms, or emotional experience. Audiences respond with concern, recognition, and their own accounts. For conditions that have been minimized or poorly understood, that visibility can matter. But attention is not the same as direction.

A campaign can succeed in getting people to talk about a condition while leaving the larger problem untouched. The public may understand that the illness is common or burdensome without understanding what is missing from the current system, what kind of progress is needed, or where their attention should go next.

Make Fibroids Count does not stop at the observation that fibroids deserve greater recognition. It directs attention toward a defined research need: developing less invasive treatment options. The objective does not feel attached to Nyong’o’s story after the fact. It grows directly from it.

She has described undergoing one myomectomy after her original diagnosis and a second after the fibroids returned. Her experience gives the campaign a clear reason to focus on treatment options that could reduce the need for invasive procedures.

The disclosure creates interest. The research objective tells people why that interest matters.

A defined need changes the celebrity’s role

Personal connection is often discussed as a reason to select a particular spokesperson. It should also help determine what the person is being asked to do.

Nyong’o is not positioned as a clinician, researcher, or authority on which treatment is right for an individual patient. She is not endorsing a pharmaceutical product. Her role is to explain, through direct experience, why the absence of sufficient research and treatment choice has consequences. That is an important boundary.

The campaign does not ask her to prove the science. It asks her to make the need for science understandable.

In a March 2026 interview with the Commonwealth Fund, Nyong’o described research as necessary to give physicians and patients better options. She also connected her decision to work with the Foundation for Women’s Health to the organization’s focus on identifying and funding neglected areas of women’s health research.

Her recognition attracts an audience that the research issue may not otherwise reach. Her experience gives the issue specificity. The Foundation provides an institutional home for the funding and research process. Each party carries the part of the work it is suited to carry.

That division is often what allows a celebrity partnership to retain credibility. The public figure does not have to become the entire campaign, and the campaign does not have to stretch the person’s experience into expertise they do not claim.

A clear objective gives the story a second act

Celebrity health disclosures often produce a brief and intense cycle of attention.

A personal interview appears. Media outlets repeat the central facts. Social responses accumulate. Then the news cycle moves on.

A defined objective gives the partnership somewhere to go after that initial moment.

A research campaign can develop through fundraising milestones, grant selection, studies, findings, education, and future discussion about what the work has revealed. The celebrity can return at appropriate moments without having to produce a new personal revelation each time the campaign needs attention.

That is important for the talent relationship as well as the communications plan.

When a campaign has no next act beyond additional media, the pressure remains on the public figure to keep supplying the story. The partnership can become dependent on increasingly intimate details, repeated accounts of pain, or a level of personal access the talent never intended to provide indefinitely.

A specific objective shifts some of that weight from the person to the work.

The public story may open the campaign, but it does not have to remain its only source of relevance.

Not every disclosure needs a fundraiser

The lesson is not that every celebrity health campaign should raise money or create a research grant.

Different conditions present different barriers. One campaign may need to improve recognition of symptoms. Another may need to direct people toward screening, credible support, or a conversation with a healthcare professional. A third may need to correct a persistent misconception that prevents patients from seeking care.

The important distinction is between naming a subject and identifying the deficit the partnership can credibly address.

“Raise awareness” is often too broad to make that decision. It describes a communications ambition, but not necessarily the work the attention should perform.

The relationship among Nyong’o’s experience, the campaign, and the research goal is easy to understand. She experienced recurrent fibroids and repeated surgery. The initiative seeks to fund research into less invasive approaches. The public does not need specialized medical knowledge to understand why those elements belong together.

That coherence matters.

A celebrity’s personal connection may be sincere while the proposed campaign action still feels remote from the story. When the link is weak, the talent can appear to have been placed beside a worthy cause rather than selected for a role only that person could perform credibly.

Celebrity recognition should lead into the field, not replace it

A public figure can bring a health issue into view. That does not mean the issue begins with the celebrity or belongs to them.

Fibroid patients, advocates, clinicians, and researchers were working on the condition long before Make Fibroids Count. Nyong’o has publicly acknowledged joining an existing community and has directed audiences toward organizations already active in the field.

That posture strengthens rather than diminishes her role.

Celebrity participation is often most useful when it brings people to work that is already credible but insufficiently visible or funded. The person opens the door. Researchers, clinicians, advocates, and patient organizations carry the work further.

Campaigns can lose that balance when the celebrity’s visibility becomes the principal measure of success. The condition begins to orbit the person, and organizations with deeper subject-matter authority become supporting characters in their own field.

The stronger arrangement uses recognition to distribute attention.

In this case, the public figure makes the research gap easier to see. The Foundation administers the research initiative. The grant creates a path for qualified investigators to pursue the scientific work.

The celebrity is central to the invitation, but not mistaken for the solution.

Start with the work, then choose the voice

Some campaigns begin with a recognizable name and search afterward for the right message, action, or organizational partner.

Make Fibroids Count illustrates the value of the reverse sequence.

The relevant question is not only whether a public figure has a real connection to the condition. It is whether that connection naturally supports a need the organization is prepared to address.

When those elements align, the partnership has more than a story. The disclosure introduces the issue. The personal experience explains the stakes. The organization gives the action credibility. The objective gives the relationship a life beyond its first wave of coverage.

Without that direction, even a sincere and widely reported disclosure can leave behind little more than a temporary increase in attention.

Celebrity recognition should not be the final product of a health campaign. It should help something else happen.

At the Amy Doner Group, we work with healthcare organizations and agencies to identify talent whose personal connection fits not only the story being told, but the work the campaign is intended to advance.

A celebrity can look ideal on the shortlist. The personal connection is credible. The audience fit is clear. The creative team can already see the campaign.

Then the talent’s representatives ask what the company expects to do with the performance after the initial production.

The answer may involve paid media, international markets, new edits, translated audio, archived content, or technology that can alter or recreate elements of the original performance. What the organization considers future flexibility may look to the talent like a materially broader commercial relationship.

By then, the candidate may have internal champions and creative may have begun forming around the person. The team is no longer evaluating the engagement from a neutral position. It is negotiating from attachment.

Usage is not paperwork that follows talent selection. The intended life of the performance is part of the talent decision itself.

A shortlist is already a rights decision

Healthcare organizations typically evaluate talent through story, disease connection, audience relevance, recognition, reputation, timing, and budget. Those factors are essential, but they do not fully define fit.

Every candidate has different expectations about where their name, image, voice, personal experience, and recorded performance may appear. A person may be well suited to a focused disease-education film but less suited to a campaign expected to expand across markets and formats. Another may support a longer relationship while remaining protective of how content can be edited or repositioned. A third may draw a firm boundary around generated speech or imagery.

Those positions do not make the person difficult. They describe different kinds of partnership.

A shortlist that ignores them is not yet a viable shortlist. It is a collection of appealing names whose practical fit remains unknown.

“Future use” is not one request

The phrase often collapses activities with very different implications. Editing approved footage is not the same as placing it in a new commercial setting. A translated version is not necessarily equivalent to a new recording. A digitally generated performance is not another cutdown.

SAG-AFTRA’s 2025 Commercials Contracts require informed consent for covered uses of a performer’s digital replica, including a reasonably specific description of the intended use. The contracts also address access, security, compensation, retention, and destruction. These provisions do not govern every celebrity engagement, but they reflect a wider expectation that generated-performance rights should not be buried in generalized language.

California’s AB 2602 similarly makes certain provisions involving new digital-replica performances unenforceable when specified conditions are met. The law is narrower than a general prohibition, but it reinforces the importance of specificity when a contract reaches beyond work the person actually performed.

Artificial intelligence did not create the tension between campaign flexibility and talent control. Healthcare organizations have long negotiated media, term, territory, editing, and renewal. It has raised the stakes because a future asset may contain words or actions the person never delivered.

Accessibility, localization, continuity, and campaign extensions may all be legitimate goals. Talent may have equally legitimate boundaries around generated speech, altered appearance, or unfamiliar contexts. When a team cannot explain what it may want to do, representatives must assess the widest plausible interpretation. That uncertainty can change interest, compensation, approvals, and trust before production begins.

The broadest grant can narrow the field

Organizations sometimes approach rights as an acquisition exercise: secure as much flexibility as possible now so the campaign will not need to renegotiate later.

That approach can discourage a candidate who would accept a more focused engagement, increase the price of rights the organization has no defined plan to use, and prolong negotiation over hypothetical scenarios.

It can also distort the talent comparison. A candidate may appear prohibitively expensive when the issue is not the person’s fee but the scope attached to the request. Another may appear easier to secure because their representatives are more permissive, even though the person is less credible for the story or less suitable for a lasting healthcare relationship.

The objective is not to obtain the broadest grant available. It is to establish a rights position that supports the campaign without unnecessarily reducing access to the right person. That balance depends on the talent, the health subject, the creative ambition, the anticipated campaign life, and the organization’s genuine plans for expansion.

In healthcare, permission and suitability are separate questions

A company may have the contractual right to use a performance and still need to determine whether a particular use remains appropriate.

Editing, placement, timing, and context can change what an audience understands. A shorter asset may retain a favorable statement while losing nearby qualification. A translated line may alter the degree of certainty conveyed by the original speaker. An older asset may remain accessible after supporting information or campaign resources have changed. A generated line may introduce words the spokesperson never delivered or reviewed.

FDA’s Office of Prescription Drug Promotion is responsible for helping ensure that prescription drug promotion is truthful, balanced, and accurately communicated. Its reviewers assess promotional materials to determine whether they are false or misleading.

A talent agreement and a healthcare review process answer different questions. The agreement establishes what the parties have authorized. Regulatory, legal, medical, and communications judgment determines whether a proposed use remains accurate, supportable, and appropriate in its new setting.

Broad rights do not guarantee a responsible path to exercising them.

Fit has to survive beyond the first shoot

A healthcare partnership can be creatively well cast and commercially miscast. A recognizable person may fit the first production while the rights, cost, approvals, and future uses make the larger relationship impractical.

Specialized talent procurement is most valuable before one name becomes difficult to reconsider. At that stage, the intended campaign life can still be assessed alongside representative expectations, creative ambition, cost, and healthcare responsibilities.

That assessment may lead to a more focused engagement, a reserved future option, a differently structured relationship, or a different talent choice. The value lies in knowing which answer fits this person, this story, this disease area, and this organization.

The strongest choice is not always the most recognizable person or the candidate with the fewest apparent restrictions. It is the person whose credibility, expectations, representatives, and willingness align with the partnership the organization can realistically sustain.

The first shoot may introduce the partnership. The decisions made before the shortlist determine whether it has somewhere credible to go next.

At the Amy Doner Group, we work with healthcare organizations and agencies to define that engagement early, identify talent whose fit extends beyond production day, and negotiate a partnership that can support the intended life of the campaign.